Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid and dicyclomine. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief. Dicyclomine is an anticholinergic antispasmodic used to relieve smooth muscle spasms.
## Primary Indications
* Painful menstruation (dysmenorrhea)
* Abdominal pain associated with smooth muscle spasm
## Adult Dosing
* **Mefenamic acid:** Typically 500 mg every 6 hours as needed, not to exceed 7 days for self-treatment or 10 days in any month.
* **Dicyclomine:** Typically 20 mg four times daily before meals and at bedtime.
* **Meftal spas:** The specific dosing for the combination product will depend on the formulation. Standard adult dosing is typically 1 tablet (containing mefenamic acid 250 mg and dicyclomine HCl 20 mg) three times a day. *Exact dosing should be confirmed with product labeling or local protocol.*
## Pediatric Dosing
* Meftal spas is generally not recommended for use in children. Safety and efficacy have not been established.
* **Mefenamic acid:** In children 6 months and older, dosing is typically 6.5 mg/kg every 6 hours.
* **Dicyclomine:** Use in infants and children is generally discouraged due to the risk of serious side effects, including respiratory depression and coma.
## Dose Adjustments
* **Renal Impairment:** Mefenamic acid should be used with caution in patients with renal impairment. Dicyclomine is renally excreted, and caution may be warranted.
* **Hepatic Impairment:** Mefenamic acid should be used with caution in patients with hepatic impairment.
* **Elderly:** Elderly patients may be at increased risk for NSAID-related adverse effects, particularly gastrointestinal bleeding and renal toxicity.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
* Gastrointestinal obstruction or atony.
* Uncontrolled narrow-angle glaucoma.
* Myasthenia gravis.
* Severe renal or hepatic impairment.
* Severe heart failure.
* Use during the third trimester of pregnancy.
## Adverse Effects
* **Common (Mefenamic acid):** Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, constipation, dizziness, headache, rash.
* **Common (Dicyclomine):** Dry mouth, blurred vision, dilated pupils, photophobia, flushing, constipation, urinary hesitancy, drowsiness, confusion.
* **Serious:**
* **NSAID-related:** Serious cardiovascular thrombotic events (MI, stroke), gastrointestinal bleeding, ulceration, perforation, renal toxicity, hepatic toxicity, hypersensitivity reactions.
* **Dicyclomine-related:** Central nervous system depression (especially in infants and children), paradoxical excitement, severe allergic reactions.
## Key Drug Interactions
* **NSAIDs:** Increased risk of bleeding with anticoagulants (e.g., warfarin) and antiplatelet agents (e.g., aspirin, clopidogrel). Increased risk of renal toxicity with ACE inhibitors, ARBs, diuretics, cyclosporine, and tacrolimus.
* **Dicyclomine:** May potentiate the effects of other anticholinergic drugs. May reduce the absorption of drugs with pH-dependent absorption (e.g., digoxin). May interact with MAO inhibitors.
## Monitoring
* **Mefenamic acid:** Monitor for signs and symptoms of GI bleeding and ulceration. Monitor renal function, especially in patients with pre-existing renal disease or those taking diuretics or ACE inhibitors. Monitor liver function.
* **Dicyclomine:** Monitor for signs of anticholinergic side effects, particularly in the elderly and in patients with underlying conditions that may be exacerbated by anticholinergics.
## Clinical Pearls
* Meftal spas should be taken with food or milk to minimize gastrointestinal upset.
* Due to the potential for drowsiness and blurred vision, patients should exercise caution when driving or operating machinery.
* The duration of use should be limited as recommended to minimize risks associated with NSAID use.
* Avoid concomitant use of other NSAIDs or salicylates unless specifically indicated and monitored.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines before making any treatment decisions. Drug information can change, and individual patient factors must be considered.*
